149 related articles for article (PubMed ID: 30687070)
1. Successful Certolizumab Pegol Treatment of Chronic Anterior Uveitis Associated with Psoriasis Vulgaris.
Yamaguchi K; Hayashi T; Takahashi G; Momose M; Asahina A; Nakano T
Case Rep Ophthalmol; 2018; 9(3):499-503. PubMed ID: 30687070
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life.
Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L
Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
Korge B; Vanhooteghem O; Lynde CW; Machovcova A; Perrussel M; Lazaridou E; Marasca C; Sarro DV; Pousa ID; Fierens F; Williams P; Shimizu S; Heidbrede T; Warren RB
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38937404
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation.
Llorenç V; Mesquida M; Sainz de la Maza M; Blanco R; Calvo V; Maíz O; Blanco A; de Dios-Jiménez de Aberásturi JR; Adán A
Ocul Immunol Inflamm; 2016; 24(2):167-72. PubMed ID: 25325834
[TBL] [Abstract][Full Text] [Related]
5. Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.
Umezawa Y; Sakurai S; Hoshii N; Nakagawa H;
Dermatol Ther (Heidelb); 2021 Apr; 11(2):513-528. PubMed ID: 33606269
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol in the treatment of psoriasis: Real-life data.
Turkmen M; Dogan S
Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.
Vender RB; Lynde CW
J Cutan Med Surg; 2022; 26(3):267-273. PubMed ID: 35134313
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.
Umezawa Y; Asahina A; Imafuku S; Tada Y; Sano S; Morita A; Sakurai S; Hoshii N; Tilt N; Nakagawa H
Dermatol Ther (Heidelb); 2021 Jun; 11(3):943-960. PubMed ID: 33886085
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy.
Imafuku S; Tada Y; Umezawa Y; Sakurai S; Hoshii N; Nakagawa H
Dermatol Ther (Heidelb); 2022 Jan; 12(1):121-135. PubMed ID: 34826124
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.
Okubo Y; Umezawa Y; Sakurai S; Hoshii N; Nakagawa H
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1397-1415. PubMed ID: 35622315
[TBL] [Abstract][Full Text] [Related]
12. PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol.
Walsh JA; Arledge T; Nurminen T; Peterson L; Stark J
J Rheumatol; 2018 Jul; 45(7):922-928. PubMed ID: 29717036
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data.
Dattola A; Cannizzaro MV; Mazzeo M; Bianchi L
Dermatol Ther (Heidelb); 2017 Dec; 7(4):485-492. PubMed ID: 29139035
[TBL] [Abstract][Full Text] [Related]
14. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
[TBL] [Abstract][Full Text] [Related]
19. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.
Mease P; Deodhar A; Fleischmann R; Wollenhaupt J; Gladman D; Leszczyński P; Vitek P; Turkiewicz A; Khraishi M; FitzGerald O; Landewé R; de Longueville M; Hoepken B; Peterson L; van der Heijde D
RMD Open; 2015; 1(1):e000119. PubMed ID: 26509074
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]